VanEck Pharmaceutical ETF vs. iShares Healthcare Fund: Which Is the Better Buy for Global Pharma Exposure in 2026?
This article from The Motley Fool compares two healthcare-focused ETFs: the iShares Global Healthcare ETF (IXJ) and the VanEck Pharmaceutical ETF (PPH). IXJ offers broad global exposure across 110 stocks including medical device and biotech firms, with a 1.50% yield and 0.4% expense ratio. PPH is more concentrated, holding 26 pharmaceutical giants, with a 2.0% yield and slightly lower expense ratio. Performance data shows PPH outperforming IXJ in year-to-date (7% vs 2%), 3-year (13.8% vs 6.6%), and 5-year (10.5% vs 4.9%) returns, though IXJ edges ahead over 10 years. PPH carries slightly more risk due to concentration. The article concludes that PPH is the better pharmaceutical ETF to buy in 2026, favoring its focused approach and higher returns.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection